Stryker reported first‑quarter profit of $745 million, up from $654 million a year earlier, as it rebounded from a cyberattack tied to tensions in Iran. The company said adjusted earnings hit $2.60 a share, below the FactSet consensus of $2.98. The hit rattled operations but did not dent the bottom line in the fourth quarter of business.

Sales climbed 2.6 % to $6.02 billion, slightly shy of analysts’ $6.34 billion forecast. Growth was strongest in MedSurg and Neurotechnology units, which rose 5 %, while Orthopaedics added a modest 0.1 %. The cyber incident forced a pause in some manufacturing lines but the company maintained supply chain continuity for healthcare providers and investors who rely on durable equipment.

The cyberattack, reportedly a retaliation for the Iran war, exposed gaps in Stryker’s IT defenses, prompting a review of cyber‑security protocols across its global facilities. Despite the setback, the company’s diversified portfolio and steady demand for medical devices helped cushion the impact, keeping earnings growth on track for shareholders and regulators who monitor cyber risks.

Investors will scrutinize whether Stryker can translate this resilience into long‑term profitability while tightening its cyber defenses. The company’s 2024 outlook remains unchanged, but executives noted a need for enhanced data protection measures. Market observers will watch quarterly guidance for signs of a return to pre‑attack performance levels for financial analysts and industry peers.